Knowledge Management System of Hefei Institute of Physical Science，CAS
| Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study | |
| Zhang, Xi1; Lian, Xue-Mei2; Gu, Xiao-Fen3; Liu, Yin4; Feng, Chang-Yan5; Li, Li6; Xu, Hui-Fang4; Du, Jing-Chang7; Zhao, Yu-Qian8; Ma, Li9; Liu, Yun-Yong10; Huang, Juan-Xiu11; Cao, Ji12; Wang, Xiao-Hui13; Du, Ling-Bin14; Duan, Shuang-Xia15; Wang, Wen-Jun16; Fan, Yan-Ping17; Yu, Yan-Qin18; Zhang, Shao-Kai4; Shi, Ji-Hai19; Qiao, You-Lin4,20 | |
| 2022-03-16 | |
| Source Publication | ANNALS OF TRANSLATIONAL MEDICINE
 |
| ISSN | 2305-5839 |
| Corresponding Author | Zhang, Shao-Kai(shaokaizhang@126.com) ; Shi, Ji-Hai(sjh@btmc.edu.cn) ; Qiao, You-Lin(qiaoy@cicams.ac.cn) |
| Abstract | Background: Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response of colorectal cancer (CRC). However, little is known about biomarker testing for CRC patients in real-life clinical practice in China. This study aimed to address the usage of biomarker testing and analyze factors related to its acceptance among Chinese patients with advanced CRC. Methods: A multicenter, cross-sectional, hospital-based clinical epidemiology study was conducted from March 2020 to March 2021. Nineteen hospitals were selected in seven geographical regions of China using stratified, multistage, nonrandomized cluster sampling. Data on demographics and clinical characteristics of each eligible CRC patient in stage III or IV diseases were recorded based on the patients' self-reporting and/ or medical records. In addition, information on whether biomarker testing [RAS, BRAF, and microsatellite instability (MSI)] was performed, the results and timing for performing biomarker testing, and the reasons for refusing biomarker testing were also recorded. Univariate and multivariate logistic regression were conducted to explore the potential factors of biomarker testing. Results: A total of 4,526 patients were enrolled in the study, of whom 41.4%, 36.1%, and 28.2% underwent RAS, BRAF, and MSI testing, respectively. RAS, BRAF, and high-level MSI (MSI-high) mutation rates in Chinese patients with advanced CRC were 37.0%, 9.9%, and 8.1%, respectively. The logistic regression analysis revealed that the treating hospital, age at diagnosis, education, family income, tumor site, history of chemotherapy and radiotherapy, and metastases were dependent factors affecting the utilization of biomarker testing in advanced CRC in China (P<0.005). Conclusions: The biomarker testing rate, especially MSI testing, is less prevalent in clinical practice for patients with advanced CRC in China. Our findings may guide the formulation of biomarker testing of CRC strategies in China and other low-income countries. |
| Keyword | Colorectal cancer (CRC) biomarker RAS BRAF microsatellite instability (MSI) |
| DOI | 10.21037/atm-22-988 |
| WOS Keyword | BRAF MUTATION ; MICROSATELLITE INSTABILITY ; 1ST-LINE TREATMENT ; POOLED ANALYSIS ; RAS MUTATIONS ; K-RAS ; CETUXIMAB ; SURVIVAL ; CHEMOTHERAPY ; POPULATION |
| Indexed By | SCI |
| Language | 英语 |
| Funding Project | Beijing Love Book Cancer Foundation ; Merck Serono Co., Ltd. |
| Funding Organization | Beijing Love Book Cancer Foundation ; Merck Serono Co., Ltd. |
| WOS Research Area | Oncology ; Research & Experimental Medicine |
| WOS Subject | Oncology ; Medicine, Research & Experimental |
| WOS ID | WOS:000779715100001 |
| Publisher | AME PUBL CO |
| Citation statistics | |
| Document Type | 期刊论文 |
| Identifier | http://ir.hfcas.ac.cn:8080/handle/334002/128690 |
| Collection | 中国科学院合肥物质科学研究院 |
| Corresponding Author | Zhang, Shao-Kai; Shi, Ji-Hai; Qiao, You-Lin |
| Affiliation | 1.Peking Univ Canc Hosp & Inst, Beijing Off Canc Prevent & Control, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China 2.Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing, Peoples R China 3.Xinjiang Med Univ, Dept Student Affairs, Affiliated Tumor Hosp, Urumqi, Peoples R China 4.Zhengzhou Univ, Henan Int Joint Lab Canc Prevent, Henan Engn Res Ctr Canc Prevent & Control, Dept Canc Epidemiol,Affiliated Canc Hosp,Henan Ca, 127 Dongming Rd, Zhengzhou 450008, Peoples R China 5.Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing, Peoples R China 6.Jinan Univ, Affiliated Hosp 1, Dept Clin Res, Guangzhou, Peoples R China 7.Chengdu Med Coll, Sch Publ Hlth, Chengdu, Peoples R China 8.Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China 9.Dalian Med Univ, Publ Hlth Sch, Dalian, Peoples R China 10.China Med Univ, Liaoning Canc Hosp & Inst, Liaoning Off Canc Control & Res, Canc Hosp, Shenyang, Peoples R China 11.Wuzhou Red Cross Hosp, Dept Gastroenterol, Wuzhou, Peoples R China 12.Guangxi Med Univ, Dept Canc Prevent & Control Off, Affiliated Hosp 1, Nanning, Peoples R China 13.Gansu Prov Canc Hosp, Dept Publ Hlth, Lanzhou, Peoples R China 14.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Canc Prevent, Canc Hosp, Hangzhou, Peoples R China 15.Xinxiang Cent Hosp, Dept Prevent Hlth, Xinxiang, Henan, Peoples R China 16.Fining Med Univ, Sch Nursing, Jining, Peoples R China 17.Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China 18.Baotou Med Coll, Clin Epidemiol Res Ctr, Dept Publ Hlth & Prevent Med, Baotou, Peoples R China 19.Baotou Med Coll, Affiliated Hosp 1, Dept Dermatol, Clin Epidemiol Res Ctr, 41 Linyin Rd, Baotou 014010, Peoples R China 20.Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Ctr Global Hlth, 9 Dongdansantiao, Beijing 100005, Peoples R China |
| Recommended Citation GB/T 7714 | Zhang, Xi,Lian, Xue-Mei,Gu, Xiao-Fen,et al. Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study[J]. ANNALS OF TRANSLATIONAL MEDICINE,2022. |
| APA | Zhang, Xi.,Lian, Xue-Mei.,Gu, Xiao-Fen.,Liu, Yin.,Feng, Chang-Yan.,...&Qiao, You-Lin.(2022).Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study.ANNALS OF TRANSLATIONAL MEDICINE. |
| MLA | Zhang, Xi,et al."Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study".ANNALS OF TRANSLATIONAL MEDICINE (2022). |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment